In a recent development, Indian pharmaceutical firm, Accord Healthcare Inc., has petitioned the U.S. Federal Circuit Court to preserve its victory in a legal battle with Purdue Pharma LP, a pharmaceutical company which filed for bankruptcy in 2019. The dispute hinged on Purdue Pharma’s unfruitful effort to invoke patent laws in an attempt to foil Accord’s initiation of a generic version of OxyContin, a widely prescribed opioid painkiller.
This plea from Accord Healthcare urges for an affirmation of the “obviousness” of its intellectual property—a crucial aspect in battles of patent litigation—that underlies their generic form of OxyContin. By doing so, it aims to underscore that the elements of their generic drug were predictable and evident to any individual skilled in the relevant medical field before the existence of Purdue Pharma’s patent.
The intricate details of the legal arguments in this matter, along with a comprehensive analysis of the finer points of this case, can be found in the original coverage of these developments at Law360.